Ipsen Completes Acquisition of Albireo
Thursday, March 02, 2023
Ipsen announced it has completed the acquisition of Albireo Pharma. The acquisition enriches Ipsen’s Rare Disease portfolio, with promising therapeutics for paediatric and adult rare cholestatic-liver diseases, innovative pipeline potential, as well as scientific and commercial capabilities. Pursuant to the transaction, Ipsen acquires all the issued and outstanding shares at a price of $42.00 per share in cash plus one non-transferable contingent value right (CVR) of $10.00 per share.
The acquisition of Albireo will greatly strengthen the portfolio of rare diseases and adds novel bile-acid modulators and an innovative pipeline to the existing rare liver portfolio. With Ipsen’s global presence, aims to bring the full potential of the approved medicines to patients around the world.
As part of the transaction, Ipsen has also acquired A3907 and A2342, two clinical-stage assets in Albireo’s pipeline. A3907 is a novel oral systemic apical sodium- dependant bile-acid transporter inhibitor currently in Phase II clinical development for primary sclerosing cholangitis (PSC).3 A2342 is an oral systemic sodium-taurocholate co-transporting peptide (NTCP) inhibitor being evaluated for viral and cholestatic diseases in a Phase I trial.
